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Abstract: Stress-activated protein kinases (SAPK) are associated with sensorineural hearing loss
(SNHL) of multiple etiologies. Their activity is tightly regulated by dual-specificity phosphatase 1
(DUSP1), whose loss of function leads to sustained SAPK activation. Dusp1 gene knockout in mice
accelerates SNHL progression and triggers inflammation, redox imbalance and hair cell (HC) death.
To better understand the link between inflammation and redox imbalance, we analyzed the cochlear
transcriptome in Dusp1−/− mice. RNA sequencing analysis (GSE176114) indicated that Dusp1−/−
cochleae can be defined by a distinct profile of key cellular expression programs, including genes of
the inflammatory response and glutathione (GSH) metabolism. To dissociate the two components,
we treated Dusp1−/− mice with N-acetylcysteine, and hearing was followed-up longitudinally by
auditory brainstem response recordings. A combination of immunofluorescence, Western blotting,
enzymatic activity, GSH levels measurements and RT-qPCR techniques were used. N-acetylcysteine
treatment delayed the onset of SNHL and mitigated cochlear damage, with fewer TUNEL+ HC and
lower numbers of spiral ganglion neurons with p-H2AX foci. N-acetylcysteine not only improved the
redox balance in Dusp1−/− mice but also inhibited cytokine production and reduced macrophage
recruitment. Our data point to a critical role for DUSP1 in controlling the cross-talk between oxidative
stress and inflammation.
Keywords: hearing; N-acetylcysteine; glutathione; antioxidants; reactive oxygen species (ROS);
mitochondria; apoptosis; inflammation; RNAseq
1. Introduction
Progressive sensorineural hearing loss (SNHL) is a bilateral and gradual impairment
of hearing as a consequence of cochlear degeneration, most commonly resulting from the
death of mechanosensitive hair cells (HCs) or/and spiral ganglion neurons (SGNs), which
are both irreplaceable in mammals. Genetic inheritance in combination with environmental
and lifestyle factors determines the onset, severity and progression of SNHL [1], which
is the most frequent sensory impairment in the elderly. The World Health Organization
estimates that over 700 million people worldwide will experience disabling hearing loss by
2050 [2]. Preventive therapies to suppress the molecular mechanisms responsible for HC
and SGN death are the most promising treatment options to avert irreversible damage.
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Oxidative stress and mitochondrial dysfunction are common triggering factors for
cochlear degeneration in all scenarios causing SNHL [3]. Accordingly, a large number
of compounds have been tested for their ability to reduce reactive oxygen species (ROS)
generation, promote the ROS scavenger system, or enhance cochlear antioxidant defenses
Among them, N-acetylcysteine (NAC) is one of the most widely investigated, and it is ad-
ministered in mice by either intraperitoneal injection or oral gavage (12.5–400 mg/kg) [4,5].
NAC oral intake is approved for human use in the range 200–1200 mg/day [4]. NAC
can stimulate, indirectly, glutathione (GSH) synthesis, acting as L-cysteine precursor, and
can also directly break disulfide bonds, acting as a reducing agent [6]. While the use of
antioxidants to restore the redox imbalance in the cochlea has proved to be effective to some
extent, in vitro and in vivo experiments revealed that the elevated levels of ROS represent
just one component of a more complex and orchestrated phenomenon involving impaired
mitochondrial quality control and function, loss of proteostasis, DNA damage and genomic
instability, apoptosis, inflammation and altered intercellular communication [7,8]. Progress
in this area is, accordingly, dependent on identifying as many molecular targets as possi-
ble in the aberrant regulatory pathways. In this context, dual-specificity phosphatase 1
(DUSP1) emerges as a central candidate.
DUSP1 is an inducible MAP kinase phosphatase (MKP), a branch of the dual specificity
phosphatase family that regulates mitogen-activated protein kinase (MAPK) activation [9].
MAPKs are specific Ser/Thr kinases that operate in a three-tier kinase cascade to integrate
signals from extracellular stimuli to direct physiological responses, including proliferation,
differentiation, motility, inflammation and/or survival. MAPKs integrate multiple highly
heterogeneous extracellular signals, including growth factors, mitogens or cytokines se-
creted from neighboring cells, as well as environmental stressors such as oxidative stress,
UV radiation, heat or osmotic shock. JNK1/2/3 and p38 isoforms (MAPK11/12/13/14)
are the major MAPKs that participate in transducing stress stimuli and, hence, are known
as stress-activated protein kinases (SAPKs) [10]. SAPKs have been reported as mediators
of the cochlear stress response to aminoglycoside ototoxicity, noise insult and aging both
in vitro and in vivo [7,11,12]. Because the overactivation of SAPKs leads to cell death, their
inhibition has been reported to promote cell survival and hearing protection after cochlear
insult in humans [13] and mice [14]. The spatiotemporal activation of SAPKs leads to
cellular fate-shifting outcomes, and thus, it is tightly regulated by feedback loops that are
ultimately based on the dephosphorylating capacity of DUSP1. DUSP1 is induced by stress
stimuli to control the magnitude and extent of SAPK activation [9,15]. It is also able, albeit
with less affinity, to dephosphorylate ERK1/2 [15]. Accordingly, DUSP1 can be considered
as a converging node for several signal transduction pathways, participating in multiple
physiological processes [16] that include cytokine production, macrophage recruitment
and inflammation resolution [17]. Mouse DUSP1 has also been reported to have a role in
glucocorticoid-mediated inflammatory repression [18], limiting cytokine production [19,20]
and inhibiting NF-κβ [21].
We recently showed that mice with genetic deficiency of Dusp1 present with exacer-
bated inflammation and generalized HC and SGN loss along aging, thus providing a good
model of premature SNHL [9]. Indeed, DUSP1 is key in the control of the progression of
SNHL and in the response to noise damage mediated by increased activity of p38α [9].
Here, we aim to deepen the understanding of the role of DUSP1 in hearing loss, which
we began to unveil in our previous paper [9]. The comparative RNAseq analysis of the
cochleae of wild type and mutant Dusp1 knockout mice shown in this manuscript sustained
our hypothesis that oxidation secondary to DUSP1 loss of action had a role in triggering
premature hearing loss. We consider that if the redox imbalance was significant, treatment
with an antioxidant should prevent hearing loss. NAC was used because its antioxidant
properties are well-known and its human use approved [4]. Therefore, NAC was used
as a pharmacological tool to prevent redox imbalance. An in-depth knowledge of the
molecular bases of SNHL with regard to DUSP1 involvement should contribute to the
development of effective therapies. In this regard, the main results of the present study are
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the following: (i) comparative RNA sequencing (RNAseq) data analysis of wild-type (WT)
and Dusp1−/− (KO) mouse cochleae revealed the aberrant expression of genes involved
in GSH metabolism, inflammation, DNA damage, apoptosis and neuronal homeostasis
in Dusp1−/− mice; (ii) antioxidant supplementation (NAC) in Dusp1−/− mice partially
recovers hearing thresholds, likely by restoring the cellular antioxidant system and limiting
cochlear damage; (iii) cochleae of NAC-treated Dusp1−/− mice show preserved mito-
chondrial integrity and limited ROS production, thus preventing a chronic inflammatory
state; and (iv) DNA damage and apoptosis are reduced in SGNs and HCs, respectively, in
NAC-treated Dusp1−/− mice.
2. Materials and Methods
2.1. Mice
Dusp1+/+ (WT), Dusp1−/− (KO) and NAC-treated Dusp1−/− (KO + NAC) mice were
used in the study (n = 25 for WT and KO, n = 15 for KO + NAC). Mice were generated on a
mixed 129S2/SvPas:C57BL/6 genetic background and were genotyped as described [22].
No sex-linked differences were noted between genotypes in hearing; thus, male and female
mice were analyzed together.
2.2. Antioxidant Treatment
For drug administration, we used the protocol of a previous study [23], with some
modifications. Briefly, fresh NAC was prepared every week at a dose of 10 g/L in drinking
water (pH ~ 7.4) and was administered for 13 weeks, beginning treatment at weaning
(week 4) up to 4 months of age (week 16). Animals were maintained under controlled
temperature and light–dark cycle conditions and received standard chow diet and water
ad libitum. To assess the impact of antioxidant treatment on auditory function, hearing
thresholds were evaluated by the auditory brainstem response (ABR) at the end of weeks 8
and 16. WT and KO mice were sacrificed, and samples were collected at both time points,
whilst KO + NAC only at the second time point.
2.3. Hearing Evaluation
Animals were anesthetized and placed cater-cornered in a sound-attenuating chamber
for recording in open field configuration 10 cm apart from the calibrated MF1 speaker. ABR
testing was performed using a RZ6-A-P1 processor (Tucker-Davis Technologies, Alachua,
FL, USA). Electrical auditory processing was collected in response to TDT click (broadband)
and tone burst (4, 8, 16, 24 and 32 kHz) stimuli. All stimuli were presented at 31 pps
rate with 10 ms acquisition time and averaged 1000 or 750 times for the click and pure
tone stimuli, respectively. The response was recorded essentially as reported [24], in 5
to 10 dB steps from maximum (90 dB SPL) to minimum (15–20 dB SPL) amplitude, and
analyzed using BioSigRZ software 5.6.0 (Tucker-Davis Technologies, Alachua, FL, USA).
The lowest intensity (SPL level) that evoked a recognizable ABR five-peak wave pattern
was established as the hearing threshold for each stimulus. ABR waves I, II, III and IV and
inter-peak I-II, II-IV and I-IV latencies were analyzed at fixed 70-dB SPL click stimulation.
Wave I amplitude and latency were further analyzed at all intensity levels.
2.4. RNA-Sequencing
Inner ear dissection was performed as described [25] and samples were frozen in
RNAlater® solution (Ambion, Foster City, CA, USA). Cochlear RNA was extracted using
the RNeasy Plus Mini kit (Qiagen, Hilden, Germany) automated on the Qiacube (Qiagen,
Hilden, Germany). For RNA sequencing, 1 µg of total RNA from cochlear RNA extracts
from 20- and 32-week-old mice was used (n = 3 per group). The average sample RNA
integrity number was 9.2–9.7 (2100 Bioanalyzer, Agilent Technologies, Palo Alto, CA, USA).
The polyA+ fraction was purified and randomly fragmented, converted to double-stranded
cDNA and processed through subsequent enzymatic treatments of end-repair, dA-tailing,
and ligation to adapters using the Illumina TruSeq Stranded mRNA Sample Preparation
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Kit (Part #15031047 Rev. D; San Diego, CA, USA). This kit incorporates dUTP during the
2nd strand cDNA synthesis, meaning that only the cDNA strand generated during 1st
strand synthesis is sequenced. The adapter-ligated library was completed by PCR using
Illumina PE primers (8 cycles). The resulting purified cDNA library was applied to an
Illumina flow cell for cluster generation and was sequenced on the Illumina HiSeq2000
platform. Single-end (50-bp) sequenced reads were analyzed with the next presso pipeline
(http://ubio.bioinfo.cnio.es/people/ograna/nextpresso/, accessed on 1 May 2017). Se-
quencing quality was checked with FastQC 0.10.1 (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/, accessed on 1 May 2017). Reads were aligned to the mouse genome
(NCBI37/mm9) with TopHat-2.0.10 [26] using Bowtie 1.0.0 [27] and Samtools 0.1.19 [28], al-
lowing 2 mismatches and 5 multi-hits. Transcript quantification and differential expression
were calculated with Cufflinks 2.2.1 [26], using the mouse NCBI37/mm9 transcript anno-
tations from https://ccb.jhu.edu/software/tophat/igenomes.shtml, accessed on 28 June
2021. Gene-set enrichment analysis (GSEA) [29] was conducted on Reactome, BioCarta and
KEGG pathways; the RNAseq gene list was pre-ranked by statistic scores, setting ‘gene set’
as the permutation method and with 1000 permutations. Only those gene sets with signifi-
cant enrichment levels (false discovery rate [FDR] q-value < 0.05) were considered. GSEA
results were visualized using Enrichment Map [30] and AutoAnnotate [31] applications
for Cytoscape 3.8.2 [32], following a described pipeline [33] and applying an FDR cutoff of
0.01 for a total of 158 enriched processes or pathways (Figure 1 and Table S1). Heatmaps
were plotted using the Heatmapper web-enabled tool [34]. RNAseq data discussed in this
publication have been deposited on NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE176114.
2.5. RT-qPCR
Inner ear dissection and RNA extraction was performed as described above. Quality
determination and cDNA generation from pooled cochlear RNA extracts (3 cochlea from
different animals per group) were performed as reported [35]. Quantitative amplification
was performed in triplicate on a Quant Studio 7 Flex PCR System (Applied Biosystems,
Foster City, CA, USA) using either commercial TaqMan probes or gene specific primers
(Table S2 and [25]). Data were collected after each amplification step and analyzed with
QuantStudio™ Real-Time PCR software 1.3 (Applied Biosystems). Hprt1 gene was used as
a housekeeping gene, and the n-fold differences were calculated using the 2−∆∆Ct method.
2.6. Cochlear Morphology and Immunohistochemistry
Sample processing for histological analysis has been previously described [25]. For
cochlear cytoarchitecture, inner ear paraffin cochlear cross sections (5 µm) from 3 mice per
experimental group were stained with hematoxylin-eosin, analyzed with a Zeiss Axiophot
microscope (Carl Zeiss, Jena, Germany) and photographed with an Olympus DP70 digital
camera (Melville, NY, USA). For immunohistofluorescence, 10 µm cryostat cross sections
(n = 3) were incubated with cytochrome c oxidase subunit I (1:100, #PA5-26688; Molecular
Probes, Eugene OR, USA), p-H2A.X (1:100, #2577; Cell Signaling Technology, Danvers, MA,
USA) or IBA1 (1:100, #Ab5076; Abcam, Cambridge, UK). A confocal laser-scanning (Zeiss
LSM710, Carl Zeiss, Jena, Germany) microscope was used to acquire stack images. For each
cochlear turn, total IBA1 intensity and mean cytochrome c oxidase subunit I intensity in
the spiral ligament and spiral ganglion, respectively, were computed with Fiji software [36]
from at least 3 mice of each genotype in 4 serial sections. p-H2A.X foci were counted in 5–10
neuronal nuclei per section in slides containing 4 serial sections from at least 3 mice of each
genotype using the Fiji 3D objects Counter plugin in confocal stack images. To differentiate
positive p-H2A.X foci from larger and less intense auto-fluorescent cytoplasmatic stress
granules in neurons, high pass intensity (value = 160) and voxel size (min = 3, max = 70)
thresholds were applied.
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2.7. Hair Cell Number Quantification and TUNEL Assay
Inner ear samples were processed, dissected and stained with Myo7a (1:150, #PT-25-
6790; Proteus, Ramona, CA, USA), and the TdT-mediated dUTP nick-end labeling (TUNEL)
(Dead-End Fluorometric TUNEL System, Promega, Madison, WI, USA) assay was used for
HC quantification and apoptosis valuation, as described [25]. Low magnification images
of organ of Corti (OC) half turns were taken with a Nikon 90i epifluorescence microscope
(Nikon Corp., Tokyo, Japan) and cochleograms were plotted using a custom Fiji plugin
for at least 3 OC whole mounts per experimental group. HC number and TUNEL+ outer
hair cells (OHCs) were counted in 200 µm of the basilar membrane in the apical, basal and
middle regions located 15–25%, 50–60% and 70–80%, respectively, from the apex. TUNEL-
positive OHCs were scored as a percentage of the total number of OHC. Representative
stack images were acquired with a Zeiss LSM710 confocal laser-scanning microscope (Carl
Zeiss, Jena, Germany) at the specified cochlear regions.
2.8. Protein Extraction and Immunoblotting
Whole cochlear pooled protein extracts were prepared from 3 mice, as described [35].
A fixed volume of extract was separated by SDS-PAGE and transferred to PVDF membranes
(0.2 µm, Bio-Rad Laboratories, Hercules, CA, USA) using the Bio-Rad Trans Blot TURBO
apparatus. Prior to antibody incubation (overnight 4 ◦C), membranes were blocked with 5%
bovine serum albumin or non-fat dried milk in 0.1% Tween, 1 mM TBS. Primary antibodies
used were as follows: rabbit anti-P-p38 (1:1000, #9211), anti-P-JNK (1:1000, #4668), anti-P-
AKT (1:1000, #9271) and anti-P-H2AX (1:1000, #2577) (all from Cell Signaling Technology,
Danvers, MA, USA), rabbit anti-P22phox (1:250, #sc-20781; Santa Cruz Biotechnology,
Dallas, TX, USA), anti-HO-1 (1:1000, #AB1284; Merck, Darmstadt, Germany), anti-MnSOD
(1:1000, #06-984; Millipore, Merck, Darmstadt, Germany), goat anti-NQO1 (1:1000, #ab2346;
Abcam) and rabbit anti-PI3K (1:15000, in-house). Immunocomplexes were visualized with
peroxidase-conjugated secondary antibodies (1 h at room temperature), and bands were
detected using the Clarity™ Western ECL Substrate (Bio-Rad) on an Image Quant LAS4000
mini digital camera (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Band densities were
quantified in triplicate using Image Quant TL software 8.1 (GE Healthcare Bio-Sciences,
Pittsburgh, PA, USA ).
2.9. Protein Carbonylation
Carbonylation of cochlear proteins was measured using the Oxyblot™ Kit (Millipore,
Merck, Darmstadt, Germany). In brief, one aliquot of pooled protein extracts from each
experimental group was derivatized with 2,4-dinitrophenylhydrazine (DR, derivatization
reaction) and a second aliquot was treated with control solution (NC, negative control).
Oxidized proteins were detected using first a primary antibody specific to the dinitrophenyl-
hydrazone residues and then an HRP-conjugated secondary antibody. Protein extraction,
electrophoresis and immunodetection were performed in triplicate as outlined above.
2.10. Measurement of Glucose-6-Phosphate Dehydrogenase, 6-Phosphogluconate Dehydrogenase
and Glutathione Reductase Activity
Mitochondrial and cytosolic fractions from two inner ears (cochlea and vestibuli) per
experimental group were isolated as described [25]. Glucose-6-phosphate dehydrogenase
(G6PD) and 6-phosphogluconate dehydrogenase (PGD) activity were measured in cytosolic
fractions [37], and glutathione reductase (GSR) activity was measured in both cytosolic
and mitochondrial fractions using the Glutathione Reductase Assay Kit (Sigma-Aldrich,
Madrid, Spain). All spectrophotometric measurements were performed at least in triplicate
in a 96-well format in a VERSA max Tunable Microplate Reader (Molecular Devices,
Sunnyvale, CA, USA). Protein concentrations were determined using the DC Protein Assay
kit (Bio-Rad Laboratories, Hercules, CA, USA ).
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2.11. Glutathione and Glutathione Disulfide Analysis
Measurement of GSH and glutathione disulfide (GSSG) levels was performed as
described [38]. Briefly, two inner ears per experimental group were homogenized in
extraction buffer (0.1% Triton X-100, 0.6% sulfosalicylic acid, 5 mM EDTA, 0.1 M potassium
phosphate pH 7.5) on ice using a Dounce tissue grinder (Wheaton, Millville, NJ, USA) and
centrifuged at 8000× g at 4 ◦C for 10 min. Then, 20 µL of supernatant was used for total
GSH measurement or was incubated for 1 h at room temperature with 2-vinylpyridine for
GSSG measurement, prior to addition of DTNB (Ellman’s reagent), glutathione reductase
and β-NADPH solutions. The reaction was measured spectrophotometrically at 412 nm
every 30 s for 2 min, and samples were run in triplicate in a 96-well format in a VERSA
max Tunable Microplate Reader (Molecular Devices). TNB (5′-thio-2-nitrobenzoic acid)
formation rates were calculated to determine total GSH and GSSG levels using linear
regression from the standard curve plots. GSH concentration was obtained by subtracting
GSSG from total GSH concentration. Protein concentrations were determined using the
DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
2.12. Statistical Analysis
Sample size was estimated to obtain a 90% statistical power with a significance level of
0.05, using data from previous experiments and calculating Cohen’s d value. Data analysis
was performed with IBM SPSS 25.0 (IBM Corp., Armonk, NY, USA). Statistical significance
was assessed by one-way analysis of variance (ANOVA) after the Shapiro–Wilk and Levene
test for determination of normal distribution of data and equality of variances, respectively.
Bonferroni or Tamhane tests were used as appropriate when differences were obtained.
Results were considered statistically significant at a p-value < 0.05.
3. Results
3.1. Dusp1 Deficiency Affects Cellular Programs Involved in Cochlear Homeostasis
We carried out RNAseq analysis of Dusp1+/+ and Dusp1−/− cochleae in 20- and 32-
week-old mice. RNAseq datasets were used to run GSEA (Figure 1 and Table S1). Of the
158 enriched pathways in 20-week-old Dusp1−/− cochlea, 41 pathways were directly related
to the immune system, and 17 were also enriched in 32-week-old mice. Similarly, 21 DNA-
related pathways were enriched in 20-week-old Dusp1−/− cochleae, and 12 (including DNA
repair pathways) were also enriched in the 32-week-old mouse cochlear samples. Intrinsic
and extrinsic apoptotic pathways were also enhanced at 20 but not at 32 weeks. Moreover,
18 pathways related to neural homeostasis were negatively enriched in Dusp1−/− cochleae
at 20 weeks, as compared with Dusp1+/+ cochleae, and eight of them (including neuronal
system and glutamatergic synapse pathways) remained negatively enriched at 32 weeks.
We also observed gene enrichment for the oxidative phosphorylation process in 20-week-
old Dusp1−/− cochleae, which pointed to an increase in mitochondrial ROS production
by a highly active electron transport chain. By contrast, the mitochondrial biogenesis
program driven by the peroxisome proliferator-activated receptor γ coactivator 1α (PGC1A)
pathway was negatively enriched, suggesting the reduced generation of new mitochondrial
content and impaired organelle dynamics and function. Of note, these two phenomena
correlated with the enhancement of the antioxidant GSH metabolism pathway in 20-
week-old Dusp1−/− mice, which was maintained at 32 weeks of age (Figure 2A), possibly
to compensate/overcome mitochondrial dysfunction and oxidative damage. Overall,
these results indicate that deficiency in DUSP1 activity in mice impacts cochlear redox
homeostasis, mitochondrial quality control, apoptosis and inflammation.
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Figure 1. Gene-set enrichment analysis of RNAseq data sets from 20- and 32-week-old Dusp1+/+ and Dusp1−/− cochlea.
Enrichment analysis visualization for identification of altered gene sets (nodes). Gene sets derive from Reactome, KEGG and
BioCarta databases. Node size denotes gene set number. Differentially enriched gene sets in 20-week-old Dusp1−/− mice
are designated by node fill while node border designates 32-week-old data. Normalized enrichment value (NES) for each
time point is illustrated in a color scale from blue (negative enrichment) to red (positive enrichment). No representation
of the gene set at either time point is shown by a grey node fill or grey border, respectively. Connection between nodes is
represented by lines. Line width symbolizes number of genes shared by both nodes. Most interesting nodes are numbered
and listed (1–42). Related nodes are grouped in modules and labeled accordingly. Related modules share the same color.
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Figure 2. Impact of N-acetylcysteine administration for glutathione metabolism. (A) Glutathione (GSH) metabolism (KEGG
database) heatmap generated from differential expression data derived from RNAseq. (B) Scheme illustrating GSH biosynthe-
sis, extracellular recycling and N-acetylcysteine (NAC) antioxidant power. GSH and NAC appear in green; glutathione
Antioxidants 2021, 10, 1351 9 of 23
synthesis and recycling enzymes appear in black capital letters: GCL (glutamate-cysteine ligase), GS (glutathione syn-
thetase), GGT (gamma glutamyl transferase); glutathione precursors: Cys (cysteine), Glu (glutamate) and Gly (glycine);
oxidized protein disulfide bonds in red (S-S). (C) Experimental design illustrating the start and end-time points of NAC
administration (weaning-16 weeks), hearing evaluation (auditory brainstem response [ABR]) testing time points (8 and
16 weeks), experimental groups and sampling time points. (D) GSH, glutathione disulfide (GSSG) levels and GSH:GSSG
ratio from pooled samples of 2 inner ears of 8- and 16-week-old wild-type (WT), Dusp1 knock-out (KO) and NAC-treated
Dusp1 KO mice. All measurements were performed in triplicate. GSH and GSSG values are presented relative to milligram
of protein. (E) GSR (glutathione reductase) activity in cytosolic and mitochondrial fractions from pooled samples of
2 inner ears per condition. Measurements were performed in triplicate, and values are presented relative to milligram of
protein. (F) RT-qPCR gene expression levels of GSH-related enzymes from whole cochlea pooled samples from 3 mice per
condition. Expression levels were calculated as 2−∆∆Ct (RQ) from triplicate measurements using Hprt1 as a reference gene
and normalized to levels in 8-week-old WT mice. All data are presented as mean ± SEM. Statistical significance between
genotypes and time points was analyzed by one-way ANOVA: * vs. KO, # vs. WT, $ 8-week-old mice vs. 16-week-old mice
(*, $ p < 0.05; **, ##, $$ p < 0.01; ***, $$$ p < 0.001).
3.2. N-Acetylcysteine Treatment of Dusp1−/− Mice Has a Positive Impact on Cochlear
Glutathione Metabolism
We hypothesized that the gene upregulation of the GSH metabolism pathway in
Dusp1−/− cochleae might be a consequence of increased ROS production by over-
functioning mitochondria that likely drives early and progressive hearing loss in Dusp1−/−
mice. Accordingly, enhancing GSH synthesis with NAC might be a strategy to counteract
redox imbalance (Figure 2B). To test this, we supplied NAC (10 g/L in drinking water) to
3-week-old Dusp1−/− mice for 13 weeks and then evaluated hearing loss progression by
ABR in the three experimental groups—WT, KO and KO + NAC—at 8 and 16 weeks of
age. Samples were collected at both time points for untreated groups and only at the end
time point for NAC-treated Dusp1−/− mice (Figure 2C). We found that GSH levels were
higher and GSSG levels were lower in 8-week-old Dusp1−/− inner ears than in equivalent
Dusp1+/+ inner ears, resulting in a higher GSH:GSSG ratio (Figure 2D). These differences
were not sustained in 16-week-old Dusp1−/− mice, which showed lower levels of reduced
and oxidized forms than Dusp1+/+ mice and similar GSH:GSSG ratio levels (Figure 2D).
At this time point, inner ear GSH and GSSG levels were higher in NAC-treated Dusp1−/−
mice than in untreated Dusp1−/− mice but were not significantly different from those in
Dusp1+/+ mice. Inner ear GSR activity in both cytosolic and mitochondrial extracts was
lower in 16-week-old WT and KO + NAC groups than in equivalent KO groups (Figure 2E).
GSR activity in both compartments increased from 8 to 16 weeks of age in the untreated
KO group (Figure 2E).
Finally, RT-qPCR analysis of genes related to cochlear GSH synthesis revealed that
expression of the antioxidant enzyme glutathione peroxidase 1 (Gpx1) was higher in the
untreated KO group than in the WT and KO + NAC groups (Figure 2F). An eventual
higher GPX1 activity would require, from the higher GSR activity observed in Dusp1−/−
mice, maintaining the GSH pool and catalyzing the hydrogen peroxide reduction. Of note,
NAC treatment specifically reduced the cochlear expression of the GSH recycling enzyme,
gamma glutamyl transferase 1 (Ggt1), as compared with untreated groups (Figure 2F).
3.3. N-Acetylcysteine Treatment Delays Hearing Loss Onset and Reduces Hair Cell Death in
Dusp1−/− Mice
We next performed hearing tests in the three experimental groups at 8 and 16 weeks
of age. ABR analysis showed that NAC administration protected against hearing loss
in Dusp1−/− mice, with intermediate hearing thresholds between those of untreated
Dusp1−/− mice and Dusp1+/+ mice (Figure 3A). Specifically, NAC-treated Dusp1−/− mice
and Dusp1+/+ mice displayed lower hearing thresholds for the click and tone burst stimuli
than Dusp1−/− mice at 8 and 16 weeks of age, although with evident age-related differences
illustrated by the characteristic progressive high frequency hearing loss pattern in all mouse
groups. NAC-mediated protection at the end-time point was evident for the frequencies
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located in the middle regions of the basilar membrane (8, 16 and 24 kHz) and when
the cochleae were multifrequency stimulated (click stimulus). Threshold shifts between
both time points (Figure S1A) suggested that the antioxidant power provided by NAC
was particularly effective in the first weeks of treatment, as evidenced by the faster sound
conduction in 8-week-old NAC-treated Dusp1−/−, but not later, as revealed by ABR latency
analysis (Figure S1B–D).
Figure 3. Comparative hearing evaluation, cochlear cytoarchitecture and organ of Corti degeneration. (A) Audiograms
representing click and tone burst stimuli (4, 8, 16, 24 and 32 kHz) auditory brainstem response (ABR) thresholds of 8- and
Antioxidants 2021, 10, 1351 11 of 23
16-week-old wild-type (WT), Dusp1 knock-out (KO) and NAC-treated Dusp1 KO mice. Data are presented as mean ± SEM
of at least 15 mice per condition. Statistical significance between genotypes was analyzed by one-way ANOVA: * vs. KO,
# vs. WT (*, # p < 0.05; **, ## p < 0.01; *** p < 0.001). (B) Representative basal, middle and apical turns hematoxylin-eosin
stained cochlear mid-modiolar microphotographs of the organ of Corti (OC) (a–c, g–i and m–o) and spiral ganglion (SG)
(d–f, j–l and p–r). SG close-ups (d’–f’, j’–l’ and p’–r’). Scale bars: 25 µm in a, 50 µm in d and 25 µm in d’. Asterisks and
arrowheads indicate the absence or presence, respectively, of hair cells and fibers. (C) Representative confocal images of
TUNEL-stained (green) basal, middle and apical basilar membrane regions of 16-week-old WT, Dusp1 KO and NAC-treated
Dusp1 KO mice co-immunolabeled with Myo7a (red). Asterisks and arrowheads indicate hair cell (HC) loss and TUNEL+
nuclei, respectively. Scale bar: 50 µm. (D) Inner (IHC) and outer (OHC) hair cell number per 200 µm of basal, middle or
apical basilar membrane regions. (E) Percentage of TUNEL+ OHCs in 200 µm of basal, middle or apical basilar membrane
sections. Data are presented as mean ± SEM of 3 mice per condition. Statistical significance between genotypes was
analyzed by one-way ANOVA: * vs. KO, # vs. WT (*, # p < 0.05; **, ## p < 0.01; *** p < 0.001).
In accordance with the hearing evaluation findings, histological analysis of cochlear
sections revealed better preservation of the OC and SGNs in the basal and middle turns of
16-week-old NAC-treated Dusp1−/− mice than of untreated Dusp1−/− mice (Figure 3B).
No anatomical alterations were observed in cochleae of Dusp1+/+ mice, whereas untreated
Dusp1−/− mice displayed a flat OC and neuronal fiber degeneration in the basal turn.
NAC-treated Dusp1−/− mice exhibited basal turn OHC loss with no alterations in the
SG. Untreated-Dusp1−/− mice showed patchy OHC loss in the middle turn that was not
observed in the other two groups, as expected from the ABR analysis. Next, we performed
TUNEL assays and HC Myo7a immunostaining in OC whole mounts (Figure 3C). HC
counts confirmed the alterations observed by hematoxylin-eosin staining, with significant
inner (IHC) and outer (OHC) loss in the basal turn cochlea of Dusp1−/− mice as compared
with NAC-treated Dusp1−/− and Dusp1+/+ mice (Figure 3D). Accordingly, the percentage
of apoptotic OHCs in the basal turn was higher in untreated Dusp1−/− mice than in the
other two groups (Figure 3E).
3.4. N-Acetylcysteine Administration Modulates Redox Systems and Limits Reactive Oxygen
Species Production in Dusp1−/− Cochleae
To better understand how NAC treatment modulates the cochlear antioxidant defense
and ROS production systems in Dusp1−/− mice, we studied the expression levels of key
redox genes. Gene expression analysis showed that Nrf2, Nqo1, Sod2 and Prdx6 levels were
higher in 16-week-old Dusp1+/+ mice than in younger mice (Figure 4A); however, the over-
all expression profile indicated that NAC administration did not stimulate antioxidant gene
expression, which was similar between untreated and NAC-treated Dusp1−/− mice. In fact,
the expression of several genes (Keap1, Sirt1, Sesn2 and G6pd) was lower in cochleae of NAC-
treated Dusp1−/− mice than in equivalent untreated mice when compared with Dusp1+/+
mice, whereas Ho1 expression was lower in NAC-treated cochleae than in the other two
groups. By contrast, P22phox, a component of the O2·− generating NADPH oxidase (NOX)
complex, increased in 16-week-old Dusp1−/− mice, and this was not evident in equivalent
NAC-treated Dusp1−/− mice, which had levels similar to those of Dusp1+/+ mice. The same
expression pattern was observed for Ucp2, an important mitochondrial carrier that controls
mitochondria-derived ROS generation in the respiratory chain and whose expression is
stimulated upon oxidative stress. The cochlear expression of Ucp1 was preserved by NAC
treatment in Dusp1−/− mice as compared with untreated Dusp1−/− and Dusp1+/+ mice, as
both latter groups showed a marked reduction in expression when compared with levels
in 8-week-old mice. UCP1 generates heat by leaking protons to the mitochondrial matrix
and increasing mitochondrial permeability. Finally, the cochlear expression of the nitric
oxide isoforms iNos and nNos was higher in 16-week-old Dusp1+/+ mice than in 8-week-old
counterparts and was unaffected (iNos) or lower (nNos) in equivalent Dusp1−/− with or
without NAC supplementation (Figure 4B).
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Figure 4. Impact of N-acetylcysteine administration for cochlear redox homeostasis. (A,B) RT-qPCR gene expression levels
of redox enzymes from whole cochlea pooled samples from 3 mice per condition. Expression levels were calculated as
2−∆∆Ct (RQ) from triplicate measurements using Hprt1 as a reference gene and normalized to levels in 8-week-old wild-type
(WT) mice. Data are presented as mean ± SEM. (C) Glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate
dehydrogenase (PGD) activity from pooled inner ear cytosolic fractions of two mice per condition. Measurements were
performed in triplicate, and values are presented relative to milligram of protein. Data are presented as mean ± SEM.
(D) Cochlear oxidative protein carbonylation levels of pooled cochlear protein extracts from 3 mice per condition analyzed
with the Oxyblot™ Kit. Derivatized protein extracts (DR) are shown together with non-derivatized extracts (NC) in the
representative blot image. Quantification was performed in triplicate, and levels were referred to those of PI3K. Data are
presented as a box plot, mean value is plotted as a filled circle and whiskers represent min and max values. (E) Western
blotting of pooled cochlear protein extracts from 3 mice per condition. All protein levels are referred to those of PI3K
and normalized to data from 16-week-old WT mice. Data are presented as mean ± SEM. Statistical significance between
genotypes and time points was analyzed by one-way ANOVA: * vs. KO, # vs. WT, $ 8-week-old mice vs. 16-week-old mice
(*, #, $ p < 0.05; **, ##, $$ p < 0.01; ***, ###, $$$ p < 0.001).
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Antioxidant defense, particularly the GSH system, is highly dependent on the reduc-
tive power of NADPH, which is produced mainly in the cytosol by sequential reactions
catalyzed by G6PD and PGD. Enzymatic measurements revealed higher activity of both en-
zymes in 8- and 16-week-old untreated and NAC-treated Dusp1−/− mice than in Dusp1+/+
mice (Figure 4C). We also assessed the extent of oxidative damage by analyzing protein
carbonylation, finding that NAC administration failed to prevent the formation of these
protein modifications in 16-week-old Dusp1−/− mice (Figure 4D). Analysis of HO1 and
SOD2 protein levels revealed a different pattern of expression to that expected from the
mRNA expression data, indicating the likely post-transcriptional regulation of these pro-
teins. Of note, P22PHOX protein levels mirrored the mRNA expression data (Figure 4E),
supporting the idea that NAC effectively suppresses NOX-derived O2·− generation. Finally,
to evaluate pro-apoptotic and survival signaling we studied SAPK and AKT phosphory-
lated levels, respectively. We observed clear activation of cochlear JNK in NAC-treated
Dusp1−/− mice compared with the other two groups, whereas AKT was slightly activated
in untreated Dusp1−/− mice as compared with Dusp1+/+ mice (Figure 4E).
3.5. N-Acetylcysteine Administration Protects Mitochondria and Restrains DNA Damage in
Spiral Ganglion Neurons
Increased ROS generation and inefficient oxidative phosphorylation are closely linked
to impaired mitochondrial function and quality control. Immunolabeling of SGN for
mitochondrial complex IV (cytochrome C oxidase)—used as a marker of mitochondrial
integrity—revealed evident differences between groups, with significantly stronger neuron
immunostaining in NAC-treated Dusp1−/− mice, both in the basal and middle cochlear
turns, than in untreated Dusp1−/− mice (Figure 5A,B); no differences were observed
between Dusp1+/+ and untreated Dusp1−/− mice.
To further study energy metabolism and the generation of new mitochondrial mass,
we measured the expression levels of the PGC-1 family members (Pgc1α, Pgc1β), in ad-
dition to downstream genes and canonical mitochondrial genes (Figure 5C). Expression
data indicated that the mitochondrial biogenesis program was stimulated in 16-week-old
Dusp1+/+ mice, as evidenced by the higher expression levels of regulatory (Pgc1α, Pgc1β,
Pparα, Tfb2m and Alas1) and electron transport chain component (Sdha, Uqcrc2, Mtco1 and
Mtap6) genes and citrate synthase (Cs) when compared with younger mice. This induction
of gene expression was not evident in NAC-treated or untreated Dusp1−/− mice, with the
expression of most genes significantly reduced at this age in both groups (Figure 5C). This
accords with the downregulation of the PGC1A pathway in Dusp1−/− mice revealed by
RNAseq (Figure 1).
Redox dysregulation may lead to DNA damage, which was highlighted in the GSEA.
To evaluate this, cochlear sections were stained for the DNA damage marker phospho-
rylated histone 2A.X (p-H2A.X) (Figure 5D), and foci number were quantified in SGN
nuclei (Figure 5E). The percentage of SGNs with >5 p-H2A.X foci per nucleus was higher
in the middle turn cochlea from untreated Dusp1−/− mice than from the other two groups.
Of note, p-H2A.X levels in whole cochlear protein extracts were significantly lower in
NAC-treated Dusp1−/− mice than in untreated Dusp1−/− mice (Figure 5F).
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Figure 5. N-acetylcysteine administration preserves mitochondria and reduces DNA damage foci in Dusp1−/− spiral
ganglion neurons. (A) Representative basal and middle turn cochlear spiral ganglion (SG) cross-cryosections of 16-week-old
wild-type (WT), Dusp1 knock-out (KO) and NAC-treated Dusp1 KO mice immunolabeled for mitochondrial complex IV
(green). Scale bar: 20 µm in a. (B) Positive stained area intensity of the SG was quantified in 3 mice per condition in at least
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3 serial sections per turn. Data are presented as a box plot, mean value is plotted as a filled circle and whiskers represent
min and max values. (C) RT-qPCR gene expression levels of mitochondrial proteins and biogenesis program genes from
whole cochlea pooled samples from 3 mice per condition. Expression levels were calculated as 2−∆∆Ct (RQ) from triplicate
measurements using Hprt1 as a reference gene and normalized to levels in 8-week-old WT mice. Data are presented as
mean ± SEM. (D) Representative basal and middle turn cochlear SG cross-cryosections of 16-week-old WT, Dusp1 KO
and NAC-treated Dusp1 KO mice immunolabeled for p-H2A.X in green (a–f). Dashed lines: neuron in close ups (a’–f’).
Arrowheads indicate positive foci. Scale bar: 10 µm in a and 2.5 µm in a’. (E) Percentage of SG neuron (SGN) nuclei with
more than 5 p-H2A.X foci. p-H2A.X foci were counted in 5–10 neuronal nuclei per section in 4 serial sections per turn from
at least 3 mice per condition. Data are presented as a box plot, mean value is plotted as a filled circle and whiskers represent
min and max values. (F) Western blotting of pooled cochlear protein extracts from 3 mice per condition. p-H2A.X data are
relative to those for PI3K and normalized to data from 16-week-old WT mice. Data are presented as mean ± SEM. Statistical
significance between genotypes and time points was analyzed by one-way ANOVA: * vs. KO, # vs. WT, $ 8-week-old mice
vs. 16-week-old mice (*, # p < 0.05; **, ##, $$ p < 0.01; ***, ###, $$$ p < 0.001).
3.6. N-Acetylcysteine Administration Normalizes the Inflammatory Response and Macrophage
Recruitment in Dusp1−/− Cochlea
Chronic inflammation is a common feature of aberrant ROS production, which stim-
ulates the inflammatory response in a positive feedback loop to ultimately disrupt cell
and tissue homeostasis. In this context, DUSP1 is a key regulator of cell fate in response
to oxidative and inflammatory stimuli. To further understand how loss of Dusp1 impacts
the regulation of these two pathways, we studied the production of inflammatory medi-
ators in the 3 groups of mice (Figure 6A). Gene expression analysis of cochleae revealed
a marked induction of proinflammatory cytokine gene expression of Tnfα, Il1β, Il6 and
Il18 in Dusp1−/− mice from 8 to 16 weeks. Even at the earlier age tested, cytokine ex-
pression levels were higher in Dusp1−/− mice than in Dusp1+/+ mice with the exception
of Il18. Il1β expression also increased from 8 to 16 weeks in Dusp1+/+ mice, albeit to a
much lesser extent. Of note, cytokine expression levels were similar between NAC-treated
Dusp1−/− mice and Dusp1+/+ mice, indicating that NAC blunts the inflammatory response.
A similar NAC response was observed for the expression levels of Tgfβ1, Mpo, Foxp3 and
Kim1. Overall, these results suggest that the induction of inflammatory gene expression
observed in Dusp1−/− cochleae was secondary to the oxidative imbalance, as it could be
repressed, albeit incompletely, with NAC. To further confirm this, we tested for the pres-
ence of macrophages in the spiral ligament of cochlear sections by IBA1 immunolabeling
(Figure 6B). Results showed stronger IBA1 staining in Dusp1−/− basal and middle cochlear
turns than in equivalent sections from Dusp1+/+ mice. NAC administration effectively
limited macrophage infiltration in the middle turn but not in the basal turn (Figure 6C),
which correlates well with our data on cochlear damage and hearing thresholds.
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Figure 6. Cochlear exacerbated inflammatory response and macrophage recruitment in Dusp1−/− mice is limited by
N-acetylcysteine administration. (A) RT-qPCR gene expression levels of inflammatory mediators from whole cochlea pooled
samples from 3 mice per condition. Expression levels were calculated as 2−∆∆Ct (RQ) from triplicate measurements using
Hprt1 as a reference gene and normalized to levels in 8-week-old wild-type (WT) mice. Data are presented as mean ±
SEM. (B) Representative basal and middle turn cochlear spiral ligament (Spl) cross-cryosections of 16-week-old WT, Dusp1
knock-out (KO) and NAC-treated Dusp1 KO mice immunolabeled for IBA1 in red (a–f). Arrowheads highlight positive
macrophages staining. Spl close ups (a’–f’). Scale bar: 40 µm in a and 25 a’. (C) IBA1 quantification in the spiral ligament.
Staining intensity was quantified in 3 mice per condition in at least 3 serial sections per turn. Data are presented as a box
plot, mean value is plotted as a filled circle and whiskers represent min and max values. Statistical significance between
genotypes and time points was analyzed by one-way ANOVA: * vs. KO, # vs. WT, $ 8-week-old mice vs. 16-week-old mice
(**, ##, $$ p < 0.01; ***, ###, $$$ p < 0.001).
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4. Discussion
DUSP1 appears to be a converging node for stress-related inflammation and oxidative
stress pathways in the cochlea. DUSP1 contributes to redox homeostasis, inflammatory
response and, consequently, to hearing preservation. Our findings indicate that administra-
tion of the antioxidant NAC to Dusp1-deficient mice mitigates, at least in part, the adverse
effects caused by DUSP1 loss-of-function and delays the onset of hearing loss. It is likely,
however, that DUSP1 has broader functions, and thus NAC administration fails to fully
restore hearing in Dusp1-deficient mice.
Cochlear stress triggers the activation of pro-apoptotic and survival signaling path-
ways through MAPK cascades [9,39], and the magnitude of cross-talk between these
pathways likely tips the balance in one direction or the other [40]. A uniqueness of DUSP1
is its ability to control multiple pathways and to orchestrate cellular responses to multiple
stimuli [15]. Our high-throughput cochlear transcriptome profiling provides valuable data
on the contribution of DUSP1 to the molecular mechanisms underlying hearing loss. As
expected, pathways related to immune system were among the most affected by Dusp1
deletion in mice, both at 20 and 32 weeks of age. Pro-inflammatory cytokines activate
SAPK signaling pathways during the acute phase of the inflammatory response, which
can ultimately trigger apoptosis. In this line, tumor necrosis factor-α (TNFα) is one of
the most investigated factors involved in HC death pathways in vivo and in vitro—either
by the intrinsic mitochondrial cascade or through the binding of ligands to cell surface
death receptors (extrinsic pathway) [41]. Concomitant with immune cell recruitment, the
expression of TNFα increases rapidly after cochlear damage, activating nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κβ) and stimulating the production
of other cytokines, chemokines and adhesion molecules [42]. TNFα and NF-κβ signaling,
cytokine, chemokine, cell adhesion, phagocytosis and pathways related to intrinsic and
extrinsic apoptotic cascades were prominent in the enriched pathways in cochleae from
20-week-old Dusp1−/− mice. We speculate that Dusp1 deletion renders the cochlea unable
to resolve the pro-inflammatory response, contributing to HC and SGN apoptosis [9,17].
The importance of DUSP1 for neuronal homeostasis was also evident in our study,
as illustrated by the downregulation of neuronal system pathways in Dusp1−/− cochleae.
Neuroprotective roles have previously been ascribed to DUSP1, and reduced levels have
been related to neurological disorders [43]. Our data show that several pathways related to
neurodegenerative diseases (including Huntington’s, Alzheimer’s and Parkinson’s disease)
were enriched in the absence of DUSP1. Pathways related to DNA processes were also
conspicuous in Dusp1−/− cochlea. Among them, DNA damage pathways including DNA
repair, ATM and ATR-BRCA pathways were upregulated. Because of its capacity to inhibit
apoptotic signals, DUSP1 has been widely studied in vivo and in vitro as a proto-oncogene
and is associated with tumor progression in several types of cancer [44], which agrees with
the changes in cell cycle and cancer-related pathways in our dataset.
Mitochondrial function and maintenance of energetic integrity are essential for cellular
homeostasis. Based on our data, mitochondrial quality control and biogenesis regulation
in the cochlea are likely to be impaired in the absence of DUSP1 [45], as revealed by the
downregulation of PGC1α and the enhanced oxidative phosphorylation pathways in 20-
week-old Dusp1−/− cochlea. Mitochondria are extremely dynamic and environmentally
sensitive organelles that can adapt rapidly to adverse conditions to preserve energetic
supply [46]. Even mild mitochondrial stress has been proposed to protect the cell through
increased ROS signaling as an adaptative response to reduce vulnerability to additional
metabolic anomalies [47]. Indeed, mitochondria produce up to the 90% of all intracellular
ROS, which are associated with cellular respiration, making them one of the main targets
of oxidative damage. Loss of DUSP1 function might render cochlear cells incapable
of adapting to a pro-oxidant environment, leading to overwhelmed mitochondria and
damage [48]. This is consistent with the sustained gene enrichment for GSH metabolism
observed in 20- and 32-week-old Dusp1−/− mice, likely induced to restore redox balance.
In this sense, metabolism and inflammation are both closely linked to ROS signaling [49],
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which might account for the exacerbated inflammatory response observed in Dusp1−/−
mice. These findings suggest that increased ROS production and mitochondrial dysfunction
trigger the inflammation and apoptotic pathways activated in Dusp1−/− cochlea [9,39,50].
This is supported by our finding that the administration of a GSH prodrug restores redox
balance and lessens the impact of DUSP1 loss-of-function for cochlear homeostasis.
In anticipation of the oxidative imbalance in Dusp1−/− mice, we administered NAC to
pups after weaning. Measurement of GSH levels indicated that the usage of GSH is finely
tuned in NAC-treated cochleae, with higher total GSH levels and lower GSR turnover rate
than in untreated cochleae, suggesting a reduced need for replacing GSSG to increase the
GSH pool. Accordingly, Ggt1 mRNA levels were reduced, which might indicate that NAC
provides a more efficient source of cysteine than the ATP-dependent process associated with
GSH extracellular export and recycling. Indeed, NAC administration has been reported
before to prevent progressive hearing loss in Ggt1 deficient mice, presumably by providing
cysteine [51].
In line with the above, we found that the expression of antioxidant defense enzymes
was not induced in NAC-treated cochlea samples, and no differences were observed
in protein carbonylation. It is likely that the correct combination of antioxidants with
different mechanisms of action, rather than NAC alone, would enhance the cochlear
antioxidant defense impacting simultaneously at different levels [5]. By contrast, WT
cochleae showed an age-related and coordinated induction of antioxidant genes, possibly
driven by NRF2 [52], which prevented protein oxidative modifications. However, our
results point to a limitation in ROS production at this age that correlated with a better
preservation of mitochondrial function and energetic supply in NAC-treated cochlea.
Conversely, NADPH production by G6PD and PGD was not reduced in NAC-treated
cochlea, which is particularly intriguing as NOX and GSR activities depend highly on this
cofactor [53]. In this regard, RNAseq data suggest that the distinct regulation of G6PD and
PGD in wild type and knockout mice may be a consequence of the metabolic alterations
in the pentose phosphate cycle associated with Dusp1 deficiency. Furthermore, Dusp1−/−
cochlea showed increased transcript and protein levels of P22PHOX [25], suggesting that
NADPH production could be increased to maintain the levels due to increased spend. In
contrast, we speculate that neither O2− generation (by NOX) nor GSH regeneration is
required at higher rates in NAC-treated cochlea. Therefore, NADPH is likely used by other
NADPH-dependent enzymes that participate in reductive anabolic reactions.
The mitochondrial biogenesis program was not activated in NAC-treated Dusp1−/−
mice in contrast to what we observed in WT cochleae. Nevertheless, mitochondria integrity
was preserved in NAC-treated SGNs. On this basis, we propose that early NAC admin-
istration generates a balanced redox environment in the mitochondria that prevents the
oxidative damage in the organelle [54] that would, otherwise, have a detrimental outcome,
as observed in untreated Dusp1−/− mice.
Active SAPKs promote cytokine production and leukocyte migration to injury sites.
Therefore, tight control of the activation of these kinases is key to preventing an inflamma-
tory response and the propagation of damage [17]. In this context, DUSP1 is induced in re-
sponse to inflammatory stimuli to mediate shutdown of the acute inflammation phase [55].
We found that inflammation was present at early stages in Dusp1−/− cochlea, later becom-
ing chronic with production of inflammatory mediators that contributed to severity and
propagation of damage accompanied by increased macrophage recruitment [56,57]. In this
regard, expression of the master regulator of the development and function of regulatory
T-cells, Foxp3, was induced in Dusp1−/− cochlea at 16 weeks of age. When stimulated,
regulatory T-cells aid in resolving established inflammation by suppressing immune re-
sponses of other cells and inducing them to express immunosuppressive cytokines such as
IL-10 [58]. Despite the higher Il10 expression in 16-week-old Dusp1−/− mice, the increase
was not significant and might indicate deficient activation of the inflammation resolution
phase. Specifically, IL-10 is known to induce the robust expression of Dusp1 that sustains
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mRNA levels in a feedback loop and correlates with inhibition of p38 signaling and with
IL-6 and IL-12 production in vitro [59].
Inflammation was reduced in NAC-treated mice, although it was not completely
neutralized, as illustrated by increased Tnfα, Il6 and Il18 expression levels. It is possible that
NAC contributes to preventing early ROS-driven pro-inflammatory cytokine production
and the later chronic inflammatory state [60,61], as observed in NAC-treated 16-week-old
Dusp1−/−. Nevertheless, the cellular antioxidant system is complex, and while glutathione
is the most powerful cellular antioxidant, it represents just one of the several lines of
defense against ROS. In this context, the impact of NAC administration is limited and
might explain the higher JNK activation levels [62] observed in NAC-treated 16-week-
old Dusp1−/− mice, which may have occurred earlier in chronically inflamed untreated
Dusp1−/− cochlea. We would suggest that HC loss may spread quickly in NAC-treated
mice, emulating the situation in untreated mice and supporting the idea that hearing
loss onset is lessened but not prevented by NAC. Indeed, although much lower than in
untreated mice, the gene expression of the damage biomarker kidney injury molecule 1
(KIM-1) [9] was higher in NAC-treated mice than in control mice, which also points in
this direction. Cochlear levels of KIM-1 have been reported to increase following NOX
activation and ROS generation, and ROS scavengers and NOX inhibitors attenuated this
increase [63]. Notably, Kim1 induction upon ROS generation by NOX was also observed in
the Dusp1−/− cochlea as shown by increased P22PHOX mRNA and protein levels, which
were inhibited by treatment with NAC.
Independent of ROS production, aberrant regulation of inflammation due to DUSP1
loss-of-function contributes to damage extension and hearing loss. Indeed, corticoid
treatment was previously found to reduce TNFα levels in the spiral ligament and activate
survival pathways in HCs, inhibiting JNK signaling [64]. In this context, modulation
of both mechanisms simultaneously could be a more robust strategy to ameliorate the
metabolic disturbances in Dusp1−/− cochlea. Indeed, there is evidence showing that
drug combination approaches attenuate human hearing loss [65]. In fact, protection from
oxidative stress and limited HC death were reported in patients with sudden SNHL by
combined NAC-dexamethasone treatment, but both compounds were ineffective when
administered alone [66].
Overall, our study provides evidence to consider pharmacological modulation of
DUSP1 activity as a potential treatment for hearing loss, as an alternative to current
SAPK inhibitors [13,14,67,68]. Nevertheless, given its unique physiological activity, DUSP1
induction and activity regulation is finely tuned, and so treatments would be highly
dependent on the correct timing and kinetics of both DUSP1 and the proteins involved in
the signaling pathways. It is clear that several issues need to be addressed and numerous
challenges overcome to achieve the successful modulation of DUSP1 activity [69].
5. Conclusions
We provide new insight into the role of DUSP1 in the cochlea using a combination of
transcriptomics and antioxidant treatment of Dusp1-deficient mice. We present here, for
the first time, transcriptome sequencing data from cochleae suffering unrestrained cellular
stress due to the absence of its natural regulator DUSP1. Our data improve knowledge
on the basic molecular mechanisms that orchestrate the regulation of oxidative stress,
inflammation and mitochondrial quality control in the ageing cochlea. The molecular
mechanisms underlying SNHL have multiple common aspects; thus, this work provides
information beyond ARHL. Finally, our findings point to DUSP1 as a potentially druggable
target to impair HC and SGN death in response to stress.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/antiox10091351/s1, Figure S1: Comparative hearing loss progression and sound conduction
efficiency of Dusp1+/+, Dusp1−/− and N-acetylcysteine-treated Dusp1−/− mice; Table S1: Gene sets
enriched in Dusp1−/− cochlea; Table S2: TaqMan probes and primers for RT-qPCR experiments.
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